PLEASANTON, Calif. - Movano Health (NASDAQ:MOVE) has reported progress in the FDA's 510(k) clearance process for its EvieMED Ring, a wearable medical device. The company recently received additional questions from the FDA concerning the medical aspects of the device, indicating it is in the final phase of review. Earlier this summer, Movano Health resolved initial queries regarding the wellness features and metrics of the EvieMED Ring.
John Mastrototaro, President and CEO of Movano Health, expressed confidence in addressing the FDA's follow-up questions and anticipates completing the review process. The EvieMED Ring offers both medical device functionality, including pulse oximetry, and wellness metrics that track sleep, activity, mood, energy, and more.
In a separate announcement, Movano Health revealed the resumption of direct-to-consumer orders for its Evie Ring on September 17, 2024. The company has seen a positive response to product enhancements and operational improvements, such as advanced monitoring capabilities, AI-generated insights, and overall upgrades to manufacturing, logistics, and customer service.
Founded in 2018, Movano Health aims to integrate medical-grade data into wearable technology, providing users and enterprises with trusted health data and personalized insights. The company is developing proprietary technologies to leverage data for proactive health monitoring and management across various patient populations.
This news article is based on a press release statement from Movano Health. The information provided reflects the company's current expectations and may involve risks and uncertainties that could cause actual results to differ materially. Movano Health cautions against placing undue reliance on any forward-looking statements, which are based on assumptions as of the date of the press release and are subject to change.
In other recent news, Movano Health has been making significant strides in its operations, with notable progress in the FDA review process for its EvieMED Ring. The wearable device, which provides medical and wellness metrics, is advancing towards obtaining a 510(k) clearance, particularly for its pulse oximetry feature. The company is also set to resume direct-to-consumer orders for the Evie Ring starting soon, introducing product enhancements and improved operations processes.
Movano Health reported an operating loss of $6.4 million in the second quarter, despite shipping 1,837 Evie Rings. However, the company has established collaborations with two global pharmaceutical companies and a large payer for commercial opportunities. A partnership with digital creator Heidi D'Amelio forms part of a comprehensive marketing strategy to promote the Evie Ring.
Furthermore, Movano Health has completed a blood pressure clinical study and is redesigning the device for improved sensor placement. These developments are part of the company's ongoing efforts to improve its operations and reach a broader market. Movano Health continues to emphasize the importance of wearables in monitoring chronic conditions like high blood pressure and diabetes.
InvestingPro Insights
As Movano Health (NASDAQ:MOVE) progresses through the FDA's 510(k) clearance process for its EvieMED Ring, investors should consider some key financial metrics and insights provided by InvestingPro.
According to InvestingPro data, Movano Health's market capitalization stands at $33.05 million, reflecting its status as a small-cap company in the wearable medical device sector. This valuation should be viewed in the context of the company's revenue, which was $0.85 million for the last twelve months as of Q2 2023. The substantial difference between market cap and revenue suggests investors are pricing in significant future growth potential, likely tied to the success of products like the EvieMED Ring.
However, it's crucial to note that Movano Health is currently operating at a loss. The company reported a gross profit margin of -87.21% and an operating income margin of -3198.83% for the same period. These figures align with an InvestingPro Tip indicating that the company "suffers from weak gross profit margins" and is "not profitable over the last twelve months."
Despite these challenges, Movano Health's balance sheet shows some strength. An InvestingPro Tip reveals that the company "holds more cash than debt on its balance sheet" and "liquid assets exceed short term obligations." This financial position could provide some runway as the company works towards FDA clearance and scales up its direct-to-consumer operations for the Evie Ring.
Investors should be aware that the stock has faced significant pressure, with InvestingPro data showing a one-year price total return of -62.89%. This aligns with another InvestingPro Tip stating that the "price has fallen significantly over the last year." The current stock price represents just 31.51% of its 52-week high, indicating substantial potential for recovery if the company achieves its regulatory and commercial goals.
For a more comprehensive analysis, InvestingPro offers 11 additional tips for Movano Health, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.